Compare URGN & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | URGN | ESQ |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 920.0M |
| IPO Year | 2016 | 2017 |
| Metric | URGN | ESQ |
|---|---|---|
| Price | $18.87 | $109.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $29.29 | ★ $120.33 |
| AVG Volume (30 Days) | ★ 665.3K | 79.5K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ 14.20 |
| EPS | N/A | ★ 5.87 |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $127.17 | $28.65 |
| Revenue Next Year | $73.82 | $4.95 |
| P/E Ratio | ★ N/A | $18.51 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $69.14 |
| 52 Week High | $30.00 | $119.86 |
| Indicator | URGN | ESQ |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 56.01 |
| Support Level | $18.37 | $91.62 |
| Resistance Level | $20.44 | $112.17 |
| Average True Range (ATR) | 0.91 | 3.64 |
| MACD | 0.14 | 0.36 |
| Stochastic Oscillator | 80.51 | 51.51 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.